S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Misonix Stock Forecast, Price & News

0.00 (0.00%)
(As of 11/22/2021)
Today's Range
50-Day Range
52-Week Range
2 shs
Average Volume
60,302 shs
Market Capitalization
$462.06 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MSON News and Ratings via Email

Sign-up to receive the latest news and ratings for Misonix and its competitors with MarketBeat's FREE daily newsletter.

Misonix logo

About Misonix

Misonix, Inc. is a medical device company, which engages in the design, development, manufacture and marketing of therapeutic ultrasonic medical devices. It operates through the following segments: Surgical and Wound. The Surgical segment consists of BoneScalpel and SonaStar products. The Wound segment consists of SonicOne, TheraSkin and Therion products. The company's ultrasonic medical devices are used in the following surgeries: spine, neuro, orthopedic, wound debridement, cosmetic, laparoscopic, and medical applications. Misonix was founded by Howard Alliger in 1959 and is headquartered in Farmingdale, NY.


Hedge Funds Are Buying Misonix, Inc. (MSON)
October 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Laboratory apparatus & furniture
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$74.02 million
Book Value
$7.77 per share


Net Income
$-14.47 million
Pretax Margin




Free Float
Market Cap
$462.06 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

1.53 out of 5 stars

Computer And Technology Sector

675th out of 890 stocks

Laboratory Apparatus & Furniture Industry

2nd out of 3 stocks

Analyst Opinion: 1.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Misonix (NASDAQ:MSON) Frequently Asked Questions

Is Misonix a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Misonix in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Misonix stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MSON, but not buy additional shares or sell existing shares.
View analyst ratings for Misonix
or view top-rated stocks.

How has Misonix's stock been impacted by Coronavirus (COVID-19)?

Misonix's stock was trading at $10.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MSON stock has increased by 148.5% and is now trading at $26.54.
View which stocks have been most impacted by COVID-19

How were Misonix's earnings last quarter?

Misonix, Inc. (NASDAQ:MSON) released its quarterly earnings data on Thursday, September, 2nd. The medical equipment provider reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.02. The medical equipment provider had revenue of $19.69 million for the quarter. Misonix had a negative net margin of 19.55% and a negative trailing twelve-month return on equity of 10.36%.
View Misonix's earnings history

What price target have analysts set for MSON?

3 brokers have issued 12 month price objectives for Misonix's shares. Their forecasts range from $28.00 to $28.00. On average, they anticipate Misonix's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 5.5% from the stock's current price.
View analysts' price targets for Misonix
or view top-rated stocks among Wall Street analysts.

Who are Misonix's key executives?

Misonix's management team includes the following people:
  • Stavros G. Vizirgianakis, Chief Executive Officer & Director
  • Allan R. Staley, President
  • Sharon W. Klugewicz, Chief Operating Officer
  • Joseph P. Dwyer, Chief Financial Officer, Secretary & Treasurer
  • Daniel Voic, VP-Engineering, Research & Development

What is Michael A. McManus Jr.'s approval rating as Misonix's CEO?

3 employees have rated Misonix CEO Michael A. McManus Jr. on Glassdoor.com. Michael A. McManus Jr. has an approval rating of 33% among Misonix's employees. This puts Michael A. McManus Jr. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Misonix own?

What is Misonix's stock symbol?

Misonix trades on the NASDAQ under the ticker symbol "MSON."

Who are Misonix's major shareholders?

Misonix's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.64%), Tamarack Advisers LP (2.30%), Pura Vida Investments LLC (1.25%), Geode Capital Management LLC (1.18%), Acuitas Investments LLC (0.92%) and Magnetar Financial LLC (0.90%). Company insiders that own Misonix stock include Joseph P Dwyer and Stavros G Vizirgianakis.
View institutional ownership trends for Misonix

Which institutional investors are selling Misonix stock?

MSON stock was sold by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC, Acuitas Investments LLC, BlackRock Inc., California State Teachers Retirement System, Raymond James Financial Services Advisors Inc., DAVENPORT & Co LLC, New York State Common Retirement Fund, and Deutsche Bank AG.
View insider buying and selling activity for Misonix
or view top insider-selling stocks.

Which institutional investors are buying Misonix stock?

MSON stock was bought by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, DLD Asset Management LP, K2 Principal Fund L.P., Morgan Stanley, Beryl Capital Management LLC, Barclays PLC, Gabelli Funds LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Misonix stock in the last two years include Joseph P Dwyer, and Stavros G Vizirgianakis.
View insider buying and selling activity for Misonix
or or view top insider-buying stocks.

How do I buy shares of Misonix?

Shares of MSON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Misonix's stock price today?

One share of MSON stock can currently be purchased for approximately $26.54.

How much money does Misonix make?

Misonix has a market capitalization of $462.06 million and generates $74.02 million in revenue each year.

How many employees does Misonix have?

Misonix employs 254 workers across the globe.

What is Misonix's official website?

The official website for Misonix is www.misonix.com.

Where are Misonix's headquarters?

Misonix is headquartered at 1938 NEW HIGHWAY, FARMINGDALE NY, 11735.

How can I contact Misonix?

Misonix's mailing address is 1938 NEW HIGHWAY, FARMINGDALE NY, 11735. The medical equipment provider can be reached via phone at (631) 694-9555 or via fax at 631-694-9412.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.